A turning point in the treatment of IgA nephropathy has been marked by several new publications that describe promising outcomes associated with the _targeting of key pathogenic disease processes, including the production of galactose-deficient IgA1 and IgA-containing immune complexes, complement and endothelin system activation.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
We are sorry, but there is no personal subscription option available for your country.
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rajasekaran, A., Julian, B. A. & Rizk, D. V. IgA nephropathy: an interesting autoimmune kidney disease. Am. J. Med. Sci. 361, 176–194 (2021).
Rovin, B. H. et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 100, 753–779 (2021).
Inker, L. A. et al. Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis. Am. J. Kidney Dis. 78, 340–349.e1 (2021).
Mathur, M. et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N. Engl. J. Med. 390, 20–31 (2024).
Lafayette, R. et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 105, 1306–1315 (2024).
Barratt, J. et al. Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.0000000541 (2024).
Perkovic, V. et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2410316 (2024).
Lafayette, R. et al. Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.0000000534 (2024).
Heerspink, H. J. L. et al. Atrasentan in patients with IgA nephropathy. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2409415 (2024).
Heerspink, H. J. L. et al. The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.0000000538 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.C. has served as a consultant on advisory boards and/or steering committees for Chinook, Novartis, Otsuka, STADApharm and Travere.
Rights and permissions
About this article
Cite this article
Coppo, R. Steps forward in the treatment of IgA nephropathy. Nat Rev Nephrol (2024). https://doi.org/10.1038/s41581-024-00925-y
Published:
DOI: https://doi.org/10.1038/s41581-024-00925-y
